Therapy Areas: Oncology
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
25 March 2024 -

Biotechnology companies Biocytogen Pharmaceuticals (HKEX: 02315) and ABL Bio Inc (KOSDAQ: 298380) announced on Monday that the companies have entered into a collaboration to develop innovative bispecific antibody-drug conjugates (bsADCs).

Biocytogen's RenLite mice platform, known for generating fully human antibodies, will be utilised for this venture, offering design flexibility and simplified manufacturing processes. Both companies are considering expanding their collaboration for various ADC development projects.

Beijing headquartered Biocytogen specialises in antibody-based drug research and development. Leveraging gene editing technology and proprietary platforms, including RenMice, the company has established partnerships worldwide, including with multinational pharmaceutical companies (MNCs). A sub-brand, RenBiologics, offers a library of fully human antibody sequences for collaboration. Additionally, Biocytogen provides off-the-shelf animal and cell models under BioMice, along with preclinical pharmacology and gene-editing services.

ABL Bio Inc is a Korean clinical-stage biotech company that focuses on developing antibody therapeutics for oncology and neurodegenerative diseases. With internally developed platforms like Grabody-T and Grabody-B, the company has built a pipeline of clinical and preclinical drug candidates. Grabody-T, a modular 4-1BB engaging platform, demonstrates efficacy and safety in oncology, while Grabody-B targets neurological disorders with potential breakthroughs in addressing unmet medical needs.